Repository logo
 

Study of an FBXO7 patient mutation reveals Fbxo7 and PI31 co-regulate proteasomes and mitochondria.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Al Rawi, Sara 
Simpson, Lorna 
Agnarsdóttir, Guðrún 
McDonald, Neil Q 
Chernuha, Veronika 

Abstract

Mutations in FBXO7 have been discovered to be associated with an atypical parkinsonism. We report here a new homozygous missense mutation in a paediatric patient that causes an L250P substitution in the dimerisation domain of Fbxo7. This alteration selectively ablates the Fbxo7-PI31 interaction and causes a significant reduction in Fbxo7 and PI31 levels in patient cells. Consistent with their association with proteasomes, patient fibroblasts have reduced proteasome activity and proteasome subunits. We also show PI31 interacts with the MiD49/51 fission adaptor proteins, and unexpectedly, PI31 acts to facilitate SCFFbxo7-mediated ubiquitination of MiD49. The L250P mutation reduces the SCFFbxo7 ligase-mediated ubiquitination of a subset of its known substrates. Although MiD49/51 expression was reduced in patient cells, there was no effect on the mitochondrial network. However, patient cells show reduced levels of mitochondrial function and mitophagy, higher levels of ROS and are less viable under stress. Our study demonstrates that Fbxo7 and PI31 regulate proteasomes and mitochondria and reveals a new function for PI31 in enhancing the SCFFbxo7 E3 ubiquitin ligase activity.

Description

Keywords

E3 ubiquitin ligase, Fbxo7/PARK15, Parkinson's disease, mitochondria, proteasome, Humans, F-Box Proteins, Proteasome Endopeptidase Complex, Mitochondria, Ubiquitination, Mutation, Missense, Mitophagy, Fibroblasts, Male, HEK293 Cells, Female

Journal Title

FEBS J

Conference Name

Journal ISSN

1742-464X
1742-4658

Volume Title

Publisher

Wiley
Sponsorship
Rosetrees Trust (PGL22/100035)
Parkinson's UK (G-1701)
Wellcome Trust (203151/Z/16/Z)
National Institute for Health and Care Research (IS-BRC-1215-20014)
This work is supported by funding from the BBSRC DTP to LS and HL, a Parkinson’s UK grant (G-1701) to RAB, MZ and HL, and a Rosetrees Trust Project Grant (PGL22/100035) to SAR, RAB, and HL. This research is also supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014, including the Cell Phenotyping Hub. The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. This research was funded in whole, or in part, by the Wellcome Trust 203151/Z/16/Z. NQM is supported by the Francis Crick Institute, which receives its core funding (FC001115) from Cancer Research UK, the UK Medical Research Council and the Wellcome Trust.